Table 2.
Cross-tabulation of adeno-associated virus seropositivity on day 1 in decreasing order of frequency
| AAV5 | AAV2 | AAV6 | AAV8 | AAVrh10 | n (%) | Cumulative, n (%) |
|---|---|---|---|---|---|---|
| − | − | − | − | − | 126 (24.6) | 126 (24.6) |
| + | + | + | + | + | 125 (24.4) | 251 (48.9) |
| − | + | + | + | + | 60 (11.7) | 311 (60.6) |
| − | + | − | − | − | 51 (9.9) | 362 (70.6) |
| + | − | − | − | − | 22 (4.3) | 384 (74.9) |
| − | − | − | + | − | 18 (3.5) | 402 (78.4) |
| − | + | + | − | − | 14 (2.7) | 416 (81.1) |
| − | − | − | − | + | 13 (2.5) | 429 (83.6) |
| − | + | + | − | + | 11 (2.1) | 440 (85.8) |
| − | − | + | − | − | 11 (2.1) | 451 (87.9) |
| + | + | − | − | − | 9 (1.8) | 460 (89.7) |
| + | + | + | − | + | 8 (1.6) | 468 (91.2) |
| − | − | − | + | + | 6 (1.2) | 474 (92.4) |
| − | + | + | + | − | 5 (1.0) | 479 (93.4) |
| − | + | − | − | + | 5 (1.0) | 484 (94.3) |
| + | − | − | + | − | 4 (0.8) | 488 (95.1) |
| − | + | − | + | − | 4 (0.8) | 492 (95.9) |
| + | + | + | − | − | 3 (0.6) | 495 (96.5) |
| + | − | + | + | − | 3 (0.6) | 498 (97.1) |
| − | − | + | + | − | 3 (0.6) | 501 (97.7) |
| + | + | + | + | − | 2 (0.4) | 503 (98.1) |
| + | − | + | − | − | 2 (0.4) | 505 (98.4) |
| − | + | − | + | + | 2 (0.4) | 507 (98.8) |
| − | − | + | − | + | 2 (0.4) | 509 (99.2) |
| + | + | − | − | + | 1 (0.2) | 510 (99.4) |
| + | − | − | + | + | 1 (0.2) | 511 (99.6) |
| + | − | − | − | + | 1 (0.2) | 512 (99.8) |
| − | − | + | + | + | 1 (0.2) | 513 (100.0) |
This analysis includes 513 participants with nonmissing results for all serotypes.
AAV, adeno-associated virus.